FindTrial
Sign In

Clinical study of Vitamin K2 supplementation in haemodialysis patients

Clinical study of Vitamin K2 supplementation in haemodialysis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOQ-16008326
Enrollment
Unknown
Registered
2016-04-20
Start date
2016-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end stage kidney disease

Interventions

group A:VitK2 180ug, three times a week
Group B:VitK2 80ug, three times a week
Group C:Placebo, three times a week

Sponsors

Boli Hospital of Chengdu high-tech zone
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18-80; 2. Hemodialysis mode (three times a week and continued for more than three months.

Exclusion criteria

Exclusion criteria: Patients with warfarin treatment, known intestinal malabsorption and maglinant disease were exluded; life expectancy of <3 months and inability to provide informed consent were exclusion criteria.

Design outcomes

Primary

MeasureTime frame
dp-ucMGP;hemoglobin;serum phosphorus;serum calcium;parathormone;—

Countries

China

Contacts

Public ContactZhou zhicheng

Boli Hospital of Chengdu high-tech zone

hemodoc@gmail.com+86 18980701590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026